AstraZeneca reports gefurulimab met primary endpoint in PREVAIL Phase 3 trial

Results from the global PREVAIL Phase 3 trial showed that gefurulimab met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in Myasthenia Gravis Activities of Daily Living total score compared to placebo in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis at week 26, AstraZeneca (AZN) announced. PREVAIL also met all secondary endpoints, including change from baseline in Quantitative Myasthenia Gravis total score at week four and week 26. These data were presented at the Myasthenia Gravis Foundation of America Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting in San Francisco, California. Gefurulimab demonstrated improvement from baseline in MG-ADL total score at week 26 compared to placebo. A clinically meaningful improvement was observed as early as week one, and was sustained through week 26. Additionally, a clinically meaningful improvement in key secondary endpoint, QMG total score, was seen as early as week four and was sustained through week 26.